DexCom, Inc. (NASDAQ:DXCM) is now being followed by UBS, as they initiated the stock at Neutral on November 28. Analysts at Goldman, shed their negative views on October 19 by lifting it fromSell to Neutral. The stock won favor of Northland Capital analysts who expressed their confidence in it using an upgrade from Under Perform to Market Perform on September 12.
DXCM stock dropped -0.41% in recent trade and currently has a stock-market value of $13.2B. The shares finished at $146.85, after trading as low as $144.475 earlier in the session. It hit an intraday high Thursday at $147.53. Trading activity significantly weakened as the volume at ready counter decreased to 1,347,444 shares versus 1,359,255 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 1,287,546 shares. The stock is now 131.01% above against its bear-market low of $63.57 on March 15, 2018. It has retreated -6.34% since it’s 52-week high of $156.16 reached in February. Now the market price is up 126.24% on the year and up 22.58% YTD.
Wall Street’s most bullish DexCom, Inc. (NASDAQ:DXCM) analysts are predicting the share price to blow past $180 per share during the next 12 months. The current median share price forecast by them is $163.5, suggesting that the stock could increase 11.34% in that time frame. The average price target of $157.72 calls for a nearly 7.4% increase in the stock price.
DexCom, Inc. (DXCM)’s 50 day simple moving average (SMA 50) price is $142.29 and its 200-day simple moving average (SMA 200) price is $126.02. The company’s stock currently has a total float of 88.82M shares. Its weekly volatility is hovering around 3.25% and felt 4.01% volatility in price over a month. On the upside, the share price will test short term resistance at around $148.1. On a downside, the stock is likely to find some support, which begins at $145.04. The failure to get near-term support could push it to $143.23.
Moreover, it trades for 154.58 times the next 12 months of expected earnings. Also, it is trading at rather expensive levels at just over 19.66x price/book and 12.8x price/sales. Compared to others, DexCom, Inc. is in a different league with regards to profitability, having net margins of -12.3%. To put some perspective around this, the industry’s average net margin is 13.3%. DXCM’s ROE is -23.9%, which is also considerably worse than the industry’s ROE of 16.48%. It’s also very liquid in the near term, with a current ratio of 7.6. The stock has a debt/capital of 0.
Shares of DXCM have gained 0.8% since the company’s most recent earnings report. Over the past 12 fiscal quarters, DexCom, Inc. (NASDAQ:DXCM) has topped consensus earnings estimates in 8 quarters (66%), missed earnings in 3 quarters (25%), whereas at 1 occasion EPS met analyst expectations. DXCM last reported earnings that exceeded expectations. The company raked in $0.54 per share, -99.76% change on the same period last year. That was better than consensus for $0.17. Revenue for the recent quarter stood at $338 million, up 53% on last year and above the $307.52 million predicted by analysts. For this quarter, Wall Street analysts forecast revenue in a range of $239.44 million to $279.2 million, which should be compared with $204.48 million generated last year. EPS is seen in a range of -$0.44 to $0.18, against the -$0.25 reported a year ago.